Sanofi (SNY) EBT Margin (2009 - 2026)

Sanofi (SNY) posted EBT Margin of 123.03% for Q2 2026, up 4.83% sequentially from 117.37% in Q1 2026, and up 134.0% YoY from 52.58% in Q2 2025.

Sanofi (SNY) EBT Margin (2009 - 2026) Analysis & Trends

Sanofi has reported EBT Margin for 18 years, with the latest figure at 123.03% in Q2 2026.

Quarterly EBT Margin rose 134.0% year-over-year to 123.03% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 164.97% (up 5493.0% YoY) and the FY2025 annual result came in at 14.15%, up 307.0% from the prior year.
EBT Margin climbed to 123.03% in Q2 2026 per SNY's latest filing, from 117.37% in the prior quarter.
Over five years, EBT Margin peaked at 123.03% in Q2 2026 and troughed at 127.64% in Q4 2025.
A 5-year average of 101.14% and a median of 117.7% in 2025 frame the typical range for EBT Margin.
The sharpest annual moves came in 2022 and 2025: EBT Margin soared 12288 bps in 2022, then plunged 19842 bps in 2025.
Over 5 years, EBT Margin stood at 122.83% in 2022, then slipped by 2 bps to 120.91% in 2023, then sank by 41 bps to 70.78% in 2024, then sank by 280 bps to 127.64% in 2025, then surged by 196 bps to 123.03% in 2026.
According to Business Quant data, EBT Margin over the past three periods registered 123.03%, 117.37%, and 127.64% for Q2 2026, Q1 2026, and Q4 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Johnson & Johnson	645.88 Bn	625.12 Bn	17.26 Bn	26.66%
2	AbbVie	463.46 Bn	456.89 Bn	12.70 Bn	25.18%
3	Merck	367.92 Bn	360.78 Bn	12.21 Bn	-4.11%
4	Novartis Ag	297.71 Bn	290.02 Bn	11.24 Bn	29.63%
5	Astrazeneca	255.55 Bn	250.65 Bn	12.86 Bn	18.19%
6	Amgen	234.52 Bn	220.53 Bn	7.24 Bn	27.53%
7	Gilead Sciences	178.22 Bn	175.04 Bn	6.22 Bn	-131.41%
8	Pfizer	158.57 Bn	146.88 Bn	10.94 Bn	-4.34%
9	Gsk	105.32 Bn	101.15 Bn	8.24 Bn	4.21%
10	Sanofi	54.20 Bn	46.82 Bn	10.79 Bn	127.52%

Download Data